Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Interleukin Genetics names new CEO
Previously, Mr. Bender was chief technology officer and interim CEO of Emisphere Technologies, a biopharmaceutical company. The company expects to add Mr. Bender to its board of directors
Previously, Mr. Bender was chief technology officer and interim CEO of Emisphere Technologies, a biopharmaceutical company. The company expects to add Mr. Bender to its board of directors
Tri-anim will distribute the full line of Parker’s revolutionary Flex-Tip Tracheal Tubes, which are designed to facilitate fast, easy intubation, and to prevent damage to the patient’s airway
The patent will expire in January 2025. Auxilium plans to list the patent promptly in approved drug products with therapeutic equivalence evaluations (commonly known as the Orange Book),
On-X will market this system to cardiothoracic surgeons nationwide for closed-chest ablation procedures. The system can also be used in open chest, concomitant cases. Robert Cheney, CEO of
John O’Mullane, group vice-president, R&D, Schering-Plough Consumer Health Care, said: “Schering-Plough is pleased that the FDA has approved the change to the Claritin label to help us to
Under the terms of the three-to-five year agreements, research will begin in early 2008. The assay development research relies on NUI Galway nucleic acid detection technology for both
A grant of orphan drug status provides seven years of market exclusivity for the orphan indication after approval by the FDA, as well study design assistance, and eligibility
The dosing regimen for Nebido (testosterone undecanoate) submitted in the original NDA was 1000mg given every 12 weeks. This recently completed additional Phase III trial has studied a
The multicentre, randomized Phase III trial will assess the very positive outcome of Phase I/II trial TK007 that resulted in an exceptional improvement in survival of patients by
Mycamine was approved in 2005 for the treatment of patients with esophageal candidiasis and is the only echinocandin approved for the prophylaxis of Candida infections in patients undergoing